Evidence map›Paper›PMID 40505126›Full record

ArticleJMIR AI2025

AI-Powered Drug Classification and Indication Mapping for Pharmacoepidemiologic Studies: Prompt Development and Validation.

Benjamin Ogorek, Thomas Rhoads, Eric Finkelman, Isaac R Rodriguez-Chavez

Abstract read
In one paragraph

Article in JMIR AI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Problems associated with the ATC system of drug classification.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Benjamin OgorekSpencer Health Solutions, Inc, Morrisville, NC, United States.ORCID https://orcid.org/0009-0004-5965-3097
Thomas RhoadsSpencer Health Solutions, Inc, Morrisville, NC, United States.ORCID https://orcid.org/0009-0002-6609-2721
Eric FinkelmanSpencer Health Solutions, Inc, Morrisville, NC, United States.ORCID https://orcid.org/0009-0004-6339-6281
Isaac R Rodriguez-ChavezSpencer Health Solutions, Inc, Morrisville, NC, United States.ORCID https://orcid.org/0000-0003-1787-8381

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPharmacoepidemiologic studies, which promote rational drug use and improve health outcomes, often require Anatomical Therapeutic Chemical Classification System (ATC) drug classification within real-world data (RWD) sources. Existing classification tools are expensive, brittle, or have restrictive terms of service, and lack context that may inform classification itself.

objectiveThis study sought to establish large language models (LLMs) as an assisting technology in the drug classification task. This included developing artificial intelligence prompts that reason about drugs using RWD and showing that the resulting accuracy, efficiency, and effectiveness are favorable to alternative methods.

methodsA prompt was constructed to classify aspirin as either an analgesic or antithrombotic and evaluated within 12,294 anonymized daily dose strings from a polychronic population residing in the United States and Canada. The patients used a smart medication dispenser called "spencer" and consented to the use of their data for research. The LLM prompt requested that the best and next-best second-level ATC code be returned, and grading was performed on a 3-point scale. After success in a pilot sample of 20, an inference sample of 200 was taken without replacement. Finite population inference was carried out on the proportion of outputs receiving 1 of the top 2 grades. As a benchmark, Google's Programmable Search Engine was used to query the drug name plus "ATC code" followed by regex-based extraction of ATC codes. All imperfect results were reviewed.

resultsThe population consisted of 12,294 daily dose strings from 86.26% (2908/3371) patients residing in Canada and 13.73% (463/3371) residing in the United States. A prompt using the chain-of-thought reasoning was able to distinguish between aspirin's analgesic versus antithrombotic therapeutic uses and performed well in the pilot sample. In the inferential sample, 87.5% (175/200) were graded as perfect, 5% (10/200) had a minor issue, and 7.5% (15/200) had a major issue. The estimate of the proportion of at least mostly correct classification was 92.5% (185/200, 80% CI 90.1%-94.9%). For the search-based algorithm, 82.5% (165/200) were deemed acceptable. The chain-of-thought reasoning was most helpful with supplements (eg, folic acid) when high doses indicated antianemic preparations. The problem formulation of daily dose inputs and multiple ATC outputs was sometimes incompatible with the drug (eg, pregabalin, calcitriol, and methotrexate).

conclusionsGPT-4o offers cost-effective drug classification from RWD without violating any terms of service. Using a chain-of-thought prompting technique, GPT-4o can reason about drug dosages that affect the class. The wide accessibility of LLMs gives every research team the ability to classify drugs at scale, a key prerequisite of pharmacoepidemiologic research.

Indexed as

AIAnatomical Therapeutic Chemicalartificial intelligenceATCdrug classificationgenerative language modellarge language modelsLLMsnatural language processingNLPsmart hubspencer device

Identifiers

PMID40505126
PMCPMC12203024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.